The revolutionary genetic test helps screen common genes associated with hereditary breast and ovarian cancer in women above 18 years of age
A simple blood test detects over 30 types of cancers
Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal
USFDA's industry recommendations and cancer Moonshot aim to improve lives of patients and their families
If approved, Opdivo plus chemotherapy would be the first neoadjuvant immunotherapy-based option for patients with resectable non-small cell lung cancer in the U.S.
The products are based on a combination of mushrooms and cannabinoids that have achieved a strong therapeutic effect using low concentrations of THC. The treatment is expected to be launched in Israel, US and UK in H2 2022
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
Keytruda plus Lenvima is also approved in the U.S. and Europe for the first-line treatment of adult patients with advanced RCC.
Enhertu is a HER2-directed antibody drug conjugate (ADC) being jointly developed by AstraZeneca and Daiichi Sankyo.
The Prescription Drug User Fee Action (PDUFA) date for adagrasib is December 14, 2022
Subscribe To Our Newsletter & Stay Updated
